We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

G1 Therapeutics Inc (GTHX) USD0.0001

Sell:$4.31 Buy:$4.32 Change: $0.15 (3.24%)
NASDAQ:0.12%
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$4.31
Buy:$4.32
Change: $0.15 (3.24%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$4.31
Buy:$4.32
Change: $0.15 (3.24%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.

Contact details

Address:
700 Park Offices Drive, Suite 200
RESEARCH TRIANGLE PARK
27709
United States
Telephone:
+1 (919) 2139835
Website:
https://www.g1therapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GTHX
ISIN:
US3621LQ1099
Market cap:
$233.33 million
Shares in issue:
52.20 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • John Bailey
    President, Chief Executive Officer, Director
  • John V
    Chief Financial Officer
  • Terry Murdock
    Chief Operating Officer
  • Monica Thomas
    Chief Compliance Officer, General Counsel
  • Mark Avagliano
    Chief Business Officer
  • Rajesh Malik
    Chief Medical Officer
  • Andrew Perry
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.